Business Context and Reporting Period
This Form 8-K, dated April 9, 2019, reports material events occurring on April 8, 2019, for Alnylam Pharmaceuticals, Inc. The filing details the entry into a global strategic collaboration with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNA interference (RNAi) therapeutics targeting the eye, central nervous system (CNS), and liver. Additionally, the filing reports an amendment to existing agreements with Genzyme Corporation regarding the asset fitusiran (ALN-AT3).
Key Financial Metrics and Transaction Values
The filing does not provide standard periodic financial metrics such as revenue, net income, operating cash flow, or debt levels, as this is a current report on specific events rather than a periodic financial statement. However, the following transaction-specific financial values are disclosed:
- Regeneron Upfront Payment: $400 million cash payment to Alnylam.
- Equity Transaction: Regeneron to purchase $400 million of Alnylam equity (4,444,445 shares at $90.00 per share, or convertible preferred stock).
- Regeneron Milestone Payments: Up to $200 million in early clinical development milestones for eye and CNS programs.
- Regeneron Research Funding: $2.5 million per program at initiation and $2.5 million at lead candidate identification; potential for approximately $30 million in annual discovery funding at steady state.
- Regeneron Research Term Extension Fee: Up to $400 million.
- License Agreement Milestones: Up to $150 million per collaboration product (up to $60 million development, up to $90 million commercial).
- Combination Product Milestones: Up to $325 million for anti-C5 antibody-siRNA combinations.
- Royalties: Tiered royalties ranging from low double-digits up to 20% on net sales for various programs.
Material Changes and Agreements
Regeneron Collaboration:
- Alnylam and Regeneron entered a Master Agreement to collaborate on 30 targets over an initial five-year research period.
- Regeneron leads development and commercialization for eye programs; leadership alternates for CNS and liver programs.
- Parties may enter Co-Co Collaboration Agreements to share costs and profits equally, or License Agreements where the lead party retains global responsibility.
- Regeneron will make a $400 million upfront payment and purchase $400 million of Alnylam equity.
Genzyme Amendment:
- Alnylam and Genzyme concluded the research and option phase of their Master Collaboration Agreement.
- Terms for fitusiran (ALN-AT3) were amended and restated, though material collaboration terms remain unchanged.
- Alnylam will advance an undisclosed rare genetic disease asset through IND-enabling studies at its own cost, then transition it to Genzyme for future funding.
- Genzyme was released from lock-up restrictions on its Alnylam shares and lost its right to appoint a board member.
Outlook, Risks, and Contingencies
Outlook and Management Commentary:
- The collaboration aims to address therapeutic targets in the eye, CNS, and liver.
- The Equity Transaction is expected to close in the second quarter of 2019, subject to customary conditions including HSR Act clearance.
- Regeneron will beneficially own approximately 4.0% of Alnylam's outstanding shares post-transaction.
Risks and Contingencies:
- Termination Rights: Regeneron may terminate the Master Agreement for convenience with 90 days' notice. Either party may terminate for material breach or insolvency.
- Standstill Provisions: Regeneron is bound by standstill provisions preventing it from acquiring more than 30% of Alnylam's shares or proposing an acquisition of the Company for the duration of the Research Term (plus potential extensions).
- Lock-Up Period: Regeneron agreed not to dispose of purchased shares for four years or until the termination of the Collaboration.
- Regulatory Approval: The effectiveness of the Master Agreement is subject to clearance under the Hart-Scott Rodino Antitrust Improvement Act.
Key Facts for Investor Verification
- Verify the closing of the $800 million total transaction (upfront cash + equity) with Regeneron and the resulting ownership percentage.
- Confirm the specific targets selected for the initial 30 programs under the Regeneron collaboration.
- Monitor the status of the HSR Act clearance required for the Regeneron deal to become effective.
- Review the details of the undisclosed rare genetic disease asset being transitioned to Genzyme and the associated royalty structure.
- Track the expiration of the Genzyme lock-up release and its potential impact on share volume in the market.